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 75 
Abstract 76 
Data on management of pediatric marginal zone lymphoma (MZL) are scarce. This 77 
retrospective study assessed characteristics and outcome in 66 patients <18-years-old. 78 
Forty-four (67%) had an extra-nodal (EMZL), 21 (32%) a nodal (NMZL) and one patient a 79 
splenic MZL. Thirty-three patients (50%) received a variable combination of adjuvant 80 
chemo-/immuno-/radiotherapy, whilst the remainder, including 20/21 with NMZL, entered an 81 
active observation period. Overall survival was excellent (98%±2%), although 11 patients 82 
relapsed (17%; NMZL, n=1; EMZL, n=10), 7 after any therapy, 4 after complete resection 83 
only. Conclusively, outcome of, in particular, NMZL seems to be excellent after (in)complete 84 
resection and observation only.  85 
 86 
 87 
 88 
 89 
 90 
 91 
 92 
 93 
 94 
 95 
 96 
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Introduction 97 
Marginal zone lymphoma (MZL) is a mature B-cell lymphoma and represents a 98 
distinct clinico-pathological entity of non-Hodgkin’s lymphoma (NHL). While MZL accounts 99 
for 5–17% of NHL in adulthood, it rarely occurs in children and adolescents (<2%).1 The 100 
World Health Organisation (WHO) classification recognizes three sub-entities, including 101 
nodal MZL (NMZL), extra-nodal MZL (EMZL) and splenic MZL (SMZL).2 As therapy 102 
guidelines for pediatric MZL (pMZL) have not yet been defined, treatment for both localized 103 
and disseminated disease varies a lot.3-5 To get more information about clinical 104 
presentation, treatment and outcome, two of the largest consortia in childhood NHL, the 105 
international Berlin-Frankfurt-Münster (i-BFM) Study Group and the European Intergroup for 106 
Childhood NHL (EICNHL) designed a retrospective multi-national study on this rare B-cell 107 
NHL. Herein we report on 66 patients included in this study. 108 
 109 
Results 110 
Between May 2015 and July 2016, we performed an international survey of pMZL 111 
including only patients with nationally centrally reviewed histopathology from 16 EICNHL 112 
and/or i-BFM Study Group members. Questionnaires were sent out to obtain data on 113 
demographics and disease (age, gender, stage according to the St. Jude staging system, 114 
localisation, pre-therapeutic level of serum lactate dehydrogenase (LDH), pre-existing 115 
diseases, Helicobacter pylori-infection), treatment (surgery, chemotherapy, immunotherapy, 116 
radiotherapy, antibiotics), and outcome (remission status, relapse, death, follow-up). A total 117 
of 66 patients up to 18-years-old were identified by the national NHL study centres of the 118 
respective countries including patients diagnosed with pMZL between January 1998 and 119 
July 2016. The diagnosis was based on the WHO criteria.2,6 Staging procedures as well as 120 
therapy protocols (Table 1) applied are described in detail elsewhere.7-11 Patients were 121 
included in national studies or registries and treated with informed consent from the legal 122 
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guardians. Studies were conducted in accordance with the Declaration of Helsinki and 123 
approval was delivered by the ethics committees. Event-free (EFS) and overall survival 124 
(OS) were estimated with Kaplan-Meier curves.  125 
Of the 66 patients, 21 (32%) had an NMZL, 44 (67%) an EMZL and one patient (1%) 126 
an SMZL. Median age was 14.2 years. The male-to-female ratio was 2:1. Twelve patients 127 
(18%), all of them with EMZL, had a pre-existing disorder including Sjögren’s syndrome 128 
(n=2), a common variable immunodeficiency (n=2), a primary immunodeficiency not further 129 
specified (n=3), STK4 deficiency (n=1), Crigler-Najjar-syndrome (n=1), Hodgkin’s lymphoma 130 
(n=1), squamous papilloma (n=1), and hyperandrogenism not further specified with 131 
hirsutism (n=1). 132 
After a median follow-up of 2.7 years (range 0.2–12.2 years), the 5-year EFS and OS of 133 
these 66 pMZL patients were 70%±9% and 98%±2%, respectively (Figure 1-A/B). Patient's 134 
disease course is shown in Supplementary Figure S1. 135 
 136 
Nodal marginal zone lymphoma  137 
Among the 21 NMZL patients (Supplementary Table S1), only one was female. 138 
Median age was 14.7 years. None of them had LDH levels ≥500 U/l. All but two patients had 139 
involvement of the lymph nodes in the head-and-neck region. Eighteen (86%) had stage I, 2 140 
(10%) stage III and in 1 patient (4%) stage of disease was not available. Seventeen (81%) 141 
had a complete resection, received no therapy and underwent a watch-and-wait strategy 142 
(Table 1). Another 3 of 4 patients underwent a watch-and-wait strategy (incomplete 143 
resection, n=2; resection status unclear, n=1). The remaining patient received systemic 144 
therapy.  145 
One patient relapsed after 0.3 years in a distant lymph node, had another complete 146 
resection and has been in continuous complete remission for 3.9 years. Five-year EFS and 147 
OS were 94±6% and 100%, respectively (Figure 1-C/D). 148 
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Extra-nodal marginal zone lymphoma  149 
Among the 44 EMZL patients (Supplementary Table S1), 25 (57%) were male. 150 
Median age was 13.2 years. Of the 36 patients with available LDH levels, only one had a 151 
value ≥500 U/l. Sites of involvement were: ear-nose-throat (n=16), skin (n=9), digestive tract 152 
(n=8), lungs (n=4), spleen (n=3), bone marrow (n=2), conjunctiva (n=2) and one case each, 153 
albeit not further specified, of central nervous system, orbita, breast, kidney, mediastinum 154 
and head-and-neck region. In 11 patients (25%) >1 localisation was involved, including 9 155 
with lymph node involvement. Fifteen (34%) had stage I, 12 (27%) stage II, 12 (27%) stage 156 
III, and 3 (7%) stage IV disease. Two (5%) had no stage available. Of the 8 patients having 157 
a disease confined to the digestive tract, 2 were positive for Helicobacter pylori, 1 was 158 
negative, and for 5 patients no information was available. 159 
Twenty-one (48%) received chemotherapy, 15 (34%) rituximab (4/15 without chemo- 160 
or radiotherapy) and 6 patients (14%) radiotherapy (5/6 without chemotherapy or rituximab) 161 
(Table 1). Three (7%) underwent allogeneic stem cell transplantation with 2 of them having 162 
an underlying immunodeficiency as indication. Nine of 20 patients (45%) with a complete 163 
resection received no therapy and underwent a watch-and-wait strategy. Another 3 of 24 164 
patients (13%) underwent a watch-and-wait strategy (incomplete resection, n=2; resection 165 
status unclear, n=1). 166 
Ten patients (23%) relapsed (Supplementary Table S2) after a median time of 2.1 167 
years (range 0.7–4.8 years). First-line treatment included chemotherapy (n=2), rituximab 168 
and chemotherapy (n=1), radiotherapy (n=4), and watch-and-wait strategy (n=3). Of the 169 
three patients who relapsed after chemotherapy, all had a pre-existing disorder. Six/10 170 
relapsed locally at the same site, 4/10 relapsed at new sites. One of the 10 relapses 171 
received a complete resection of recurrent disease and has been in continuous complete 172 
remission for 6.8 years. 173 
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Overall, 2 patients (5%) died, both having an underlying immunodeficiency, both 174 
dying from transplant-associated toxicity, 1 in first remission and 1 after relapse. Five-year 175 
EFS and OS were 64%±11% and 97±3%, respectively (Figure 1-C/D). 176 
 177 
Splenic marginal zone lymphoma  178 
One 17.9-years-old female patient with SMZL was treated by splenectomy only and has 179 
been in continuous complete remission for 5.2 years (Table 1, Supplementary Table S1). 180 
 181 
Discussion 182 
To our knowledge, this report including 66 patients with centrally reviewed pMZL 183 
represents by far the largest series of pMZL in childhood and adolescence reported to date. 184 
Due to its rarity, only few case reports and series have been published so far.4,5,12  185 
Our results show that pMZL is associated with male gender, older age, localized 186 
stage I/II disease, low pre-therapeutic LDH levels and a higher proportion of the EMZL 187 
subtype. Nevertheless, as we also identified stage IV patients, exclusively in EMZL, initial 188 
diagnostic work-up should always follow the modified St. Jude Staging System.13 Almost all 189 
our NMZL patients presented with isolated involvement of head-and-neck lymph nodes. In 190 
81% of them a complete resection was feasible followed by a watch-and-wait strategy and 191 
resulting in an excellent prognosis with only one relapse. In contrast, 73% of our EMZL 192 
patients were treated by systemic chemo-/immuno-/radiotherapy. Interestingly, they had a 193 
high relapse rate, despite two-thirds of the relapsed cases receiving up-front chemo-194 
/radiotherapy. Salvage therapy was successful in almost all relapsed EMZL cases resulting 195 
in a 5-year OS of 97%±3%.  196 
Taking our results into account, the indication for intense chemo-/immuno-/ 197 
radiotherapy should be re-considered to avoid unnecessary short- and long-term toxicity in 198 
pMZL.14,15 Similar strategies as for pediatric follicular lymphoma and early-stage nodular 199 
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lymphocyte-predominant Hodgkin’s lymphoma should also be pursued in pMZL.16,17 A 200 
complete resection without the risk of mutilation followed by observation may not only be 201 
justified in localised NMZL, but perhaps also in case of incomplete resection of stage I/II 202 
disease (2 of our patients) or localized relapse (1 patient).4,5 Although our study could not 203 
support the use of antibiotics in case of a proven infection, they could be tried in addition or 204 
even up-front.18 In view of the good overall survival in advanced EMZL (all but 2 of our 15 205 
stage III/IV patients are alive), low-intensity chemotherapy±rituximab could be an option 206 
whereas conventional chemotherapy±rituximab may instead be reserved for disseminated 207 
relapse or progression, as the majority of the B-NHL protocols still include anthracyclines, 208 
alkylating agents and intrathecals.10,19 209 
There are several limitations when analysing data from a multi-national retrospective 210 
survey on a very rare lymphoma subtype, all of which necessitate further evaluation in well-211 
defined prospective trials. As such, we were unable to report on genetic studies, infectious 212 
status and, in particular, on how and why the decisions were taken by the responsible 213 
physicians to follow a watch-and-wait strategy in (in)completely resected disease.12  214 
Conclusively, regardless of the therapy the patients received, it seems that pMZL 215 
does not automatically require chemotherapy due to the excellent outcome in at least 216 
localised NMZL.4,5 For more disseminated and relapsed cases, future clinical trials are 217 
necessary to establish the best therapy with the lowest amount of toxicity. 218 
 219 
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Table 1. Treatment characteristics as well as outcome of patients with pMZL, 
NMZL, EMZL, and SMZL 
pMZL NMZL EMZL SMZL 
  No. of pts. % No. of pts. % No. of pts. % No. of pts. 
 
Variable 66 21 44 1 
Treatment 
  chemotherapy § π 22 33 1 5 21 48 0 
    alone 10 0 10 
    with rituximab 12 1 11 
    with radiotherapy 1 0 1 
  rituximab § 16 24 1 5 15 34 0 
    alone 4 0 4 
    with chemotherapy 12 1 11 
    with radiotherapy 1 0 1 
  radiotherapy § 6 9 0 6 14 0 
    alone 5 5 
    with chemotherapy 1 1 
    with rituximab 1 1 
  watch-and-wait 33 50 20 95 12 27 1 
Complete resection 38 58 17 81 20 45 1 
  watch-and-wait 27 17 9 1 
Incomplete resection 26 39 3 14 23 52 0 
  watch-and-wait ~ 4 2 2 0 
Resection status n. a. 2 3 1 5 1 2 0 
  watch-and-wait 2  1  1  0 
        
Antibiotics        
  yes 8 12 1 5 7 16 0 
  no 58 88 20 95 37 84 1 
        
Allo-SCT in 1
st
 CR 
  yes 3 5 0 3 7  / 
  no 63 95 21 100 41 93 1 
Outcome 
  1
st
 CCR 54 82 20 95 33 75 1 
  relapse 11 17 1 5 10 23 0 
  death as 1
st
 event Ω 1 2 0 1 2 0 
  5-year EFS 70±9% 94±6% 64±11% 100% 
  5-year OS 98±2% 100% 97±3% 100% 
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Follow-up (y) 
  median 2,7 2,2 3,2 5,2 
  range 0,2-12,2 0,2-4,4 0,2-12,2  / 
                
 
Abbreviations: pMZL, pediatric marginal zone lymphoma; NMZL, nodal MZL; EMZL, 
extra-nodal MZL; SMZL, splenic MZL; No. of pts., number of patients; y, years; n. a., 
not available; allo-SCT, allogeneic stem cell transplantation; CR, complete remission; 
CCR, complete continuous remission; EFS, event-free survival; OS, overall survival  
 
§ 1 patient with EMZL received chemotherapy + rituximab + radiotherapy. 
Π according to NHL-BFM (n=11), LMB (n=3), and JACLS (n=1) protocols; CHOP 
(n=3), CVP (n=1), miscellaneous regimens (n=3). 
~ All 4 patients with incomplete initial resection and watch-and-wait are in remission. 
Ω Patient died from transplant-related toxicity. 
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Supplemental Table S1. Clinical and laboratory characteristics of patients with 
pMZL, NMZL, EMZL, and SMZL 
pMZL NMZL EMZL SMZL 
  No. of pts. % No. of pts. % No. of pts. % No. of pts. 
 
Variable 66 21 44 1 
Gender 
  male 45 68 20 95 25 57  / 
  female 21 32 1 5 19 43 1 
Age (y) 
  median 14,2 14,7 13,2  / 
  range 2,2-17,9 2,2-17,8 4,3-17,5 17,9 
  <10 9 14 3 14 6 14  / 
  ≥10 - 15 36 54 10 48 26 59  / 
  ≥15 - 18 21 32 8 38 12 27 1 
Pre-existing disorder 
  present  12 18 0 12 27  / 
  absent 54 82 21 100 32 73 1 
sLDH level (U/l) 
  median 216 190 249  / 
  range 129-529 129-411 133-529  / 
  <500  53 80 17 81 35 80 1 
  ≥500  1 2 0 1 2  / 
  n. a. 12 18 4 19 8 18  / 
Stage of disease 
  stage I 33 50 18 86 15 34  / 
  stage II 12 18 0 12 27  / 
  stage III 14 21 2 9 12 27  / 
  stage IV 4 6 0 3 7  1* 
  n. a. 3 5 1 5 2 5  / 
Histopathology 
  NMZL 21 32 21  100  /  / 
  EMZL 44 67  / 44  100  / 
  SMZL 1 1  /  / 1 
Sites of involvement # 
  lymph nodes 30 45 21 100 9 20 0 
  ear-nose-throat 16 24 0 16 36 0 
  skin 9 14 0 9 20 0 
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  digestive tract 8 12 0 8 18 0 
  lungs 4 6 0 4 9 0 
  spleen 4 6 0 3 7 1 
  conjunctiva 2 3 0 2 5 0 
  bone marrow 3 5 0 2 5 1* 
  other ∑ 6 9 0 6 14 0 
                
 
Abbreviations: pMZL, pediatric marginal zone lymphoma; NMZL, nodal MZL; EMZL, 
extra-nodal MZL; SMZL, splenic MZL; No. of pts., number of patients; y, years; sLDH, 
serum lactate dehydrogenase; n. a., not available 
 
# 11 patients with EMZL and 1 patient with SMZL had >1 site of involvement. 
∑ Central nervous system (n=1), head-and-neck not further specified (n=1), 
mediastinum (n=1), kidneys (n=1), orbita not further specified (n=1), breast (n=1). 
* Bone marrow involvement was questionable. 
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Supplemental Table S2. Clinical, laboratory and treatment characteristics as 
well as outcome of the 11 patients with relapsed pMZL 
relapsed MZL 
  No. of pts. % 
Variable 11 
Gender 
  male 6 55 
  female 5 45 
Age (y) 
  median 14,7 
  range 6,8-17,3 
  <10 1 9 
  ≥10 - 15 6 55 
  ≥15 - 18 4 36 
Pre-existing disorder 
  present $ 4 36 
  absent 7 64 
sLDH level (U/l) 
  median 267 
  range 138-431 
  <500  9 82 
  n. a. 2 18 
Stage of primary disease 
  stage I 5 45 
  stage II 2 18 
  stage III 3 27 
  stage IV 1 9 
Histopathology 
  NMZL 1 9 
  EMZL 10 91 
Sites of primary involvement 
  lymph nodes 1 9 
  ear-nose-throat 5 45 
  skin 4 36 
  central nervous system 1 9 
First-line treatment 
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  chemotherapy 3 27 
    alone 2 
    with rituximab 1 
  rituximab 1 9 
    alone 0 
    with chemotherapy 1 
  radiotherapy 4 27 
    alone 4 
Complete initial resection 10 91 
  watch-and-wait 4 
Incomplete initial resection 1 9 
  watch-and-wait 0 
Initial antibiotics   
  yes 0  
  no 11 100 
   
Allo-SCT in 1st CR 
  yes 1 9 
  no 10 91 
Sites of involvement at relapse # 
  lymph nodes 4 36 
  ear-nose-throat 3 27 
  skin 4 36 
  central nervous system 1 9 
Therapy of relapse 
  chemotherapy 4 36 
    alone 1 
    with rituximab 3 
  rituximab * 6 55 
    alone 2 
    with chemotherapy 3 
    with radiotherapy 1 
  radiotherapy 3 27 
    alone 2 
    with rituximab 1 
  watch-and-wait § 2 18 
Allo-SCT for relapse 1 9 
Outcome 
  2
nd
 CCR 10 91 
  death Ω  1 9 
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Follow-up (y) 
  median 6,1 
  range 0,8-12,2 
   
 
Abbreviations: pMZL, pediatric marginal zone lymphoma; NMZL, nodal MZL; EMZL, 
extra-nodal MZL; No. of pts., number of patients; y, years; sLDH, serum lactate 
dehydrogenase; n. a., not available; allo-SCT, allogeneic stem cell transplantation; 
CR, complete remission; CCR, complete continuous remission 
 
$ Sjögren’s syndrome (n=1), primary immunodeficiency not further specified (n=2), 
Crigler-Najjar-syndrome (n=1).  
# 1 patient with EMZL had >1 site of involvement. 
* 1 of the 6 patients received intralesional rituximab only.  
§ Both patients had a complete resection of their disease. 
Ω Patient died from transplant-related toxicity. 
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pMZL: n=66
NMZL: n=21 EMZL: n=44 SMZL: n=1
Complete 
resection: n=17
Supplemental figure S1: Flow chart for the disease course of the 66 patients with pMZL
Abbreviations: MZL, marginal zone lymphoma; pMZL, pediatric MZL; NMZL, nodal MZL; EMZL, extranodal MZL; SMZL, 
splenic MZL; W & W, watch-and-wait; CCR, continuous complete remission; CR, complete remission
*including 1 patient with an unclear resection status
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